Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

BridgeBio Pharma (BBIO) Income from Non-Controlling Interests (2019 - 2025)

BridgeBio Pharma's Income from Non-Controlling Interests history spans 7 years, with the latest figure at -$1.8 million for Q4 2025.

  • For Q4 2025, Income from Non-Controlling Interests rose 24.24% year-over-year to -$1.8 million; the TTM value through Dec 2025 reached -$8.0 million, down 5.56%, while the annual FY2025 figure was -$8.0 million, 5.56% down from the prior year.
  • Income from Non-Controlling Interests for Q4 2025 was -$1.8 million at BridgeBio Pharma, up from -$2.2 million in the prior quarter.
  • Across five years, Income from Non-Controlling Interests topped out at $7.3 million in Q2 2022 and bottomed at -$8.0 million in Q1 2021.
  • The 5-year median for Income from Non-Controlling Interests is -$2.4 million (2023), against an average of -$2.7 million.
  • The largest annual shift saw Income from Non-Controlling Interests skyrocketed 227.44% in 2022 before it plummeted 138.43% in 2023.
  • A 5-year view of Income from Non-Controlling Interests shows it stood at -$5.1 million in 2021, then skyrocketed by 41.65% to -$3.0 million in 2022, then increased by 26.82% to -$2.2 million in 2023, then fell by 7.29% to -$2.3 million in 2024, then increased by 24.24% to -$1.8 million in 2025.
  • Per Business Quant, the three most recent readings for BBIO's Income from Non-Controlling Interests are -$1.8 million (Q4 2025), -$2.2 million (Q3 2025), and -$1.9 million (Q2 2025).